Given our findings, which suggest that low expression of ANLN and ECT2 are associated with increased overall survival, we validated ANLN and ECT2 expression in both the TCGA PRAD cohort and an AA prostate contralateral benign-tumor-matched cohort. Here, ECT2 is linked to benign neoplasm.